【广东会GDH基因检测】检验科医师晋升考试关于ADRA2C的知识
基因检测的序列名称:
ADRA2C
人体基因序列变化与疾病表征数据库中的基因代码:
152
人体基因序列数据库中国际交流名称全称
adrenoceptor alpha 2C
中国数据库中基因全称:肾上腺素受体2C基因检测报告英文版基因简介
Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. The mouse studies revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons. The alpha2A subtype inhibited transmitter release at high stimulation frequencies, whereas the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. This gene encodes the alpha2C subtype, which contains no introns in either its coding or untranslated sequences. [provided by RefSeq, Jul 2008]
基因突变所影响的基因信息
Alpha-2-肾上腺素受体是G蛋白偶联受体超家族的成员。它们包括3个高度同源的亚型:alpha2A,alpha2B和alpha2C。这些受体在调节交感神经和中枢神经系统中肾上腺素能神经元的神经递质释放中起关键作用。小鼠研究表明,正常的突触前控制心脏中交感神经和中枢去甲肾上腺素能神经元的递质释放需要alpha2A和alpha2C亚型。alpha2A亚型在高刺激频率下抑制了递质的释放,而alpha2C亚型在较低的神经活动水平下调节了神经传递。该基因编码alpha2C亚型,该亚型在其编码序列或非翻译序列中均不ು
国际国内该碱基因序列的其他英语文字母简称:
ADRA2L2, ADRA2RL2, ADRARL2, ALPHA2CAR
基因解码对该基因序列在细胞核中的染色体所给予的编号:
该基因序列位于人类第4号染色体上。
基因解码对基因序列的正确定位
该基因序列在GRCh37版本中的起始位置坐标为:3768296;结束位置坐标为:3770253。该基因序列在GRCh38版本中的起始位置坐标为:3766569;结束位置坐标为:3768526。正确的基因信息定位是基因检测和对检测结果进行正确解读的关键。
广东会GDH基因解码对该基因的功能分类:国际版
G-protein coupled receptors/GPCRs excl olfactory receptors
基因解码对该基因的功能分类:中文版
G 蛋白偶联受体/GPCR 不包括嗅觉受体
结构与功能基因解码所揭示的该基因在细胞内发挥作用的场所(国际版):
正在通过基因解码技术进行收集、查证并编辑,请关注广东会GDH基因,获得及明更新的人类基因序列变化与疾病表征数据库的更新内容
结构与功能基因解码所揭示的该基因发挥作用的细胞内位置(中文版):
正在通过基因解码技术进行收集、查证并编辑,请关注广东会GDH基因,获得及明更新的人类基因序列变化与疾病表征数据库的更新内容
该基因序列变化后增加的疾病风险(国际版):
Fibrosis; Cardiomegaly; Heart failure; Mood Disorders; Bipolar Disorder
如果该基因突变后,风险可能增加的疾病类型(中文版):
纤维化;心脏肥大;心脏衰竭;情绪障碍;躁郁症
GWAS基因检测所建立的与该基因的疾病关联(国际版):
正在通过基因解码技术进行收集、查证并编辑,请关注广东会GDH基因,获得及明更新的人类基因序列变化与疾病表征数据库的更新内容
GWAS基因检测所解码的该基因突变会增加风险的疾病种类(中文版):
正在通过基因解码技术进行收集、查证并编辑,请关注广东会GDH基因,获得及明更新的人类基因序列变化与疾病表征数据库的更新内容
以该基因做靶点的药物(国际版):
Ziprasidone (Protein homodimerization activity);Cabergoline (Protein homodimerization activity);Ropinirole (Protein homodimerization activity);Olanzapine (Protein homodimerization activity);Clozapine (Protein homodimerization activity);Norepinephrine (Protein homodimerization activity);Mirtazapine (Protein homodimerization activity);Loxapine (Protein homodimerization activity);Pramipexole (Protein homodimerization activity);Brimonidine (Protein homodimerization activity);Clonidine (Protein homodimerization activity);Lisuride (Protein homodimerization activity);Epinephrine (Protein homodimerization activity);Tizanidine (Protein homodimerization activity);Apomorphine (Protein homodimerization activity);Risperidone (Protein homodimerization activity);Tolazoline (Protein homodimerization activity);Fenoldopam (Protein homodimerization activity);Phenoxybenzamine (Protein homodimerization activity);Oxymetazoline (Protein homodimerization activity);Carvedilol (Protein homodimerization activity);Doxepin (Protein homodimerization activity);Pergolide (Protein homodimerization activity);Bromocriptine (Protein homodimerization activity);Quetiapine (Protein homodimerization activity);Aripiprazole (Protein homodimerization activity);Paliperidone (Protein homodimerization activity);Ephedra (Protein homodimerization activity);Yohimbine (Protein homodimerization activity);Methotrimeprazine (Protein homodimerization activity);Methamphetamine (Protein homodimerization activity);Dronedarone (Protein homodimerization activity);Iloperidone (Protein homodimerization activity);OPC-28326 (Protein homodimerization activity);Epicept NP-1 (Protein homodimerization activity);Mianserin (Protein homodimerization activity);Asenapine (Protein homodimerization activity);Droxidopa (Protein homodimerization activity);Xylometazoline (Protein homodimerization activity);Lurasidone (Protein homodimerization activity);Agmatine (Protein homodimerization activity);Brexpiprazole (Protein homodimerization activity)
针对该基因所产生的突变,可能有正确效果的药物(中文版):
齐拉西酮(蛋白质同二聚化活性);卡麦角林(蛋白质同二聚化活性);罗匹尼罗(蛋白质同二聚化活性);奥氮平(蛋白质同二聚化活性);氯氮平(蛋白质同二聚化活性);去甲肾上腺素(蛋白质同二聚化活性);米氮平(蛋白质同二聚化活性);洛沙平(蛋白质同二聚活性);普拉克索(蛋白质同二聚活性);溴莫尼定(蛋白质同二聚活性);可乐定(蛋白质同二聚活性);麦角乙脲(蛋白质同二聚活性);肾上腺素(蛋白质同二聚活性);替扎尼定(蛋白质同二聚活性);阿扑吗啡(蛋白质同二聚活性);利培酮(蛋白质同二聚活性);托拉唑啉(蛋白质同二聚活性);非诺多泮(蛋白质同二聚活性);苯氧苄明(蛋白质同二聚活性);羟甲唑啉(蛋白质同二聚活性);卡维地洛(蛋白质同二聚活性);多塞平(蛋白质同二聚活性)同二聚活性);培高利特(蛋白质同二聚活性);溴隐亭(蛋白质同二聚活性);喹硫平(蛋白质同二聚活性);阿立哌唑(蛋白质同二聚活性);帕利哌酮(蛋白质同二聚活性);麻黄(蛋白质同二聚活性);育亨宾(蛋白质同二聚活性)活性);甲氧美拉嗪(蛋白质同二聚化活性);甲基苯丙胺(蛋白质同二聚化活性);决奈达隆(蛋白质同二聚化活性);伊潘立酮(蛋白质同二聚化活性);OPC-28326(蛋白质同二聚化活性);Epicept NP-1(蛋白质同二聚化活性);米安色林(蛋白质同二聚化活性);阿塞那平(蛋白质同二聚化活性);屈昔多巴(蛋白质同二聚化活性);赛洛唑啉(蛋白质同二聚化活性);鲁拉西酮(蛋白质同二聚化活性);胍丁胺(蛋白质同二聚化活性);Brexpiprazole(蛋白质同二聚化活性)